TheStreet downgraded AstraZeneca plc (ADR) (NYSE:AZN) to Hold in a report released today.
- Updated: October 14, 2016
Yesterday AstraZeneca plc (ADR) (NYSE:AZN) traded -0.63% lower at $30.64. The company’s 50-day moving average is $32.95 and its 200-day moving average is $30.86. The last closing price is down -0.69% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 1,323,420 shares of the stock traded hands, down from an average trading volume of 5,763,280
TheStreet has downgraded AstraZeneca plc (ADR) (NYSE:AZN) to Hold in a report released on 10/14/2016.
See Chart Below
AstraZeneca plc (ADR) has a 52 week low of $26.97 and a 52 week high of $35.04 with a P/E ratio of 35.02 The company’s market cap is currently $0.
In addition to TheStreet reporting its stock price target, a total of 4 brokers have issued a research note on the company. The average stock price target is $35.41 with 1 broker rating the stock a strong buy, 0 brokers rating the stock a buy, 3 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About AstraZeneca plc (ADR) (NYSE:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.